Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02102542|
Recruitment Status : Completed
First Posted : April 3, 2014
Last Update Posted : April 3, 2014
|Condition or disease|
|Hypersalivation Prevention of Drooling Bradycardia Reversal of Muscle Relaxants|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||65 participants|
|Official Title:||Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||April 2013|
A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
For reversal of neuromuscular blocking agents
Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
- Efficacy of Glyco-P as an antisialagogue [ Time Frame: 3 months ]Examine efficacy of Glyco-P for reduction of secretion and also for prevention of secretion. The secretions score ranges from 0-5 was evaluated by a person who was blinded to treatment before and after treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02102542
|Anesthesiology Department Siriraj Hospital|
|Bangkoknoi, Bangkok, Thailand, 10700|